Eris Lifesciences Limited (NSE: ERIS) stock falls 5% intraday to ₹1352.0, breaking below support in a significant breakdown.
Eris Lifesciences Limited (ERIS) reports Q4 and FY2026 results with notable growth in the insulin segment and a 37% EBITDA margin.